3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
19
Terminated
7
Withdrawn
2
Unknown
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasms
3
Leukemia, Promyelocytic, Acute
3
Neuroblastoma
1
Li-Fraumeni Syndrome
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
venetoclax
21
Cyclophosphamide
14
Cytarabine
12
Azacitidine
8
fludarabine
7
Dexamethasone
5
Daunorubicin
5
ruxolitinib
4
revumenib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
quizartinib
3
pirtobrutinib
3
gamma-Globulins
3
fludarabine phosphate
3
blinatumomab
3
Tacrolimus
3
Rituximab
3
Palliative Care
3
Inotuzumab Ozogamicin
3
Granulocyte Colony-Stimulating Factor
3
Decitabine
3
Ciprofloxacin
3
Blood Specimen Collection
3
zanubrutinib
2
ponatinib
2
pembrolizumab
2
ibrutinib
2
aldesleukin
2
acalabrutinib
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia
×
Arsenic Trioxide
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled